ArticleMolecular neurobiology2025
Presence of Astrocytic S1R/5-HT1A Heterocomplex in the mPFC: A Putative Link to S1R Activation Mediated Faster Antidepressant-Like Effects.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- GPCR heteromers: Beyond the monomeric paradigm in neuropsychiatric drug discovery.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Review
- Targeting Neuroinflammation in Depression: The Integrative Role of Sigma-1 Receptor Modulation.Journal of neurochemistry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
In the brain, sigma non-opioid intracellular receptor 1/serotonin 1A receptor (S1R/5-HT1A) heterocomplexes are primarily localized within neuronal networks and play a key role in mediating the faster antidepressant-like effects induced by S1R activation. Existing evidence further suggests that astrocytes in medial prefrontal cortex (mPFC) contribute to these S1R-triggered, accelerated antidepressant responses. To address this, the current study employed neurochemical and in vivo fiber photometry approaches to examine whether S1R/5-HT1A heterocomplexes exist in astrocytes and modulate astrocytic structure and function, and their potential behavioral consequences. Behavioral analyses demonstrated that combined administration of S1R agonist SA4503 (1.0 mg/kg, i.p.) and 5-HT1A receptor agonist 8-OH-DPAT (0.3 mg/kg, i.p.) elicited faster antidepressant-like responses, whereas 8-OH-DPAT alone at the tested dosage lacked intrinsic antidepressant activity. Utilizing in situ proximity ligation assay integrated with immunohistochemical labeling for astrocytic markers, S1R/5-HT1A heterocomplexes were identified within astrocytes of the hippocampus and mPFC. Subacute treatment with either SA-4503 alone or in combination with 8-OH-DPAT resulted in a significant elevation of these heterocomplexes in GFAP/S100β-positive cells, alongside an increase in astrocytic density, particularly within the mPFC. Pharmacological interventions further revealed that co-activation of S1R and 5-HT1A induced an enhanced astrocytic Ca
Indexed as
Identifiers
41284099What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.